Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note issued to investors on Monday morning. The firm issued a sell rating on the stock.

Separately, Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th.

Moleculin Biotech Stock Up 71.7 %

MBRX stock opened at $2.18 on Monday. The business has a 50-day moving average of $1.68 and a 200-day moving average of $2.22. Moleculin Biotech has a fifty-two week low of $0.40 and a fifty-two week high of $10.35.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.